(MLAB) Mesa Laboratories - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US59064R1095
MLAB: Life Sciences Tools, Quality Control Products, Laboratory Services
Mesa Laboratories, Inc. is a leading developer, manufacturer, and provider of life sciences tools and quality control products. With a strong presence in North America, Europe, the Asia Pacific, and other international markets, the company serves a diverse range of industries, including pharmaceuticals, medical devices, and healthcare. Mesa Labs is known for its comprehensive portfolio of products and services designed to enhance quality control and efficiency in various scientific applications.
The company operates through four primary business segments, each catering to distinct needs within the life sciences and quality control sectors. The Sterilization and Disinfection Control segment specializes in biological, chemical, and cleaning indicators. These products are crucial for assessing the effectiveness of sterilization and decontamination processes in healthcare and pharmaceutical settings. Additionally, this segment offers specialized testing and laboratory services tailored to the dental and pharmaceutical industries, ensuring compliance with stringent regulatory standards.
The Clinical Genomics segment focuses on genetic analysis, offering the MassARRAY system, a state-of-the-art tool for DNA sample analysis. This system, along with its consumables such as chips, panels, and reagent solutions, is widely used in clinical laboratories for testing inherited genetic diseases, pharmacogenetics, oncology, infectious diseases, and toxicology. The versatility of the MassARRAY system also extends to research applications, making it a valuable asset in advancing genetic understanding and personalized medicine.
The Biopharmaceutical Development segment is dedicated to providing innovative solutions for protein analysis and peptide synthesis. The product line includes Gyrolab xPand
Additional Sources for MLAB Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MLAB Stock Overview
Market Cap in USD | 757m |
Sector | Technology |
Industry | Scientific & Technical Instruments |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 1995-01-25 |
MLAB Stock Ratings
Growth 5y | -27.3% |
Fundamental | -3.81% |
Dividend | 33.2% |
Rel. Strength Industry | 16.9 |
Analysts | 3.5/5 |
Fair Price Momentum | 105.69 USD |
Fair Price DCF | 171.87 USD |
MLAB Dividends
Dividend Yield 12m | 0.40% |
Yield on Cost 5y | 0.25% |
Annual Growth 5y | 0.00% |
Payout Consistency | 96.2% |
MLAB Growth Ratios
Growth Correlation 3m | 35% |
Growth Correlation 12m | 77.3% |
Growth Correlation 5y | -80.4% |
CAGR 5y | -8.32% |
CAGR/Max DD 5y | -0.11 |
Sharpe Ratio 12m | 0.50 |
Alpha | 6.56 |
Beta | 1.45 |
Volatility | 53.03% |
Current Volume | 24.4k |
Average Volume 20d | 27.3k |
As of March 14, 2025, the stock is trading at USD 122.33 with a total of 24,367 shares traded.
Over the past week, the price has changed by -11.49%, over one month by -15.90%, over three months by -3.99% and over the past year by +16.63%.
Neither. Based on ValueRay Fundamental Analyses, Mesa Laboratories is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -3.81 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MLAB as of March 2025 is 105.69. This means that MLAB is currently overvalued and has a potential downside of -13.6%.
Mesa Laboratories has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold MLAB.
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, MLAB Mesa Laboratories will be worth about 119.4 in March 2026. The stock is currently trading at 122.33. This means that the stock has a potential downside of -2.39%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 150 | 22.6% |
Analysts Target Price | 133.3 | 9% |
ValueRay Target Price | 119.4 | -2.4% |